CDKN2A and cancer: However, due to proximity to CDKN2A on Chr9p21, MTAP is co-deleted with CDKN2A in 15-40% of human cancers, resulting in accumulation of unmetabolized MTA and attenuation of endogenous PRMT5 activity.